This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Further Observations

IRVING H. LEOPOLD, M.D.; P. ROBB McDONALD, M.D.

Arch Ophthal. 1948;40(2):176-188.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

DI-ISOPROPYL fluorophosphate (DFP) has been shown to have a marked and prolonged miotic effect in normal¹ and in glaucomatous eyes.^1b It has been shown to lower intraocular tension in these eyes. Furthermore, there is evidence that these effects are brought about entirely by inactivation of cholinesterase, and not by direct action on the iris and ciliary muscle.² Although in this respect the pharmacologic effects of DFP resemble those of physostigmine and neostigmine, the DFP—cholinesterase combination is an irreversible one.³ None of the methods successfully employed to split physostigmine and cholinesterase will break down this combination. Because of these properties of DFP and, more especially, because of the prolonged effect of very dilute preparations when locally applied to the normal eye, this drug was tested for its efficacy in the therapy of glaucoma.^1b

The initial studies indicated that DFP in 0.05 and 0.1 per cent concentrations . . . [Full Text PDF of this Article]

Author Affiliations
PHILADELPHIA

From the Department of Ophthalmology, Hospital of the University of Pennsylvania, and Wills Hospital.

Footnotes
The DFP used for these experiments was supplied by Merck & Co., Inc., Rahway, N. J.

Read before the Section on Ophthalmology at the Ninety-Seventh Annual Session of the American Medical Association, Chicago, June 24, 1948.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?